Clinical Trial Update: Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation [Phase 1, Phase 2]

View source ↗

Summary

Novartis is conducting a platform study of JDQ443 in combination regimens for KRAS G12C-mutant solid tumors, including non-small cell lung cancer and colorectal…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Cancer
• Non-small Cell Lung Cancer

Drugs mentioned

• JDQ443 (JDQ443)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: KRAS G12C Mutant Solid Tumors, Carcinoma, Non-Small Cell Lung | Phase 1, Phase 2 | Status: ACTIVE_NOT_RECRUITING